NUZ
NEURITHERA FPO [NUZ]
Healthcare · ASX Small Cap
$0.0850 +37.1%
Updated 9 Sep 2026 · Signals refresh every scan
Appeared in 3 consecutive scansFirst seen: 2026-02-25
Get alerts when NUZ triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Active Signals
Bullish Signals
- MACD momentum is picking up steam
- Pressing against the upper Bollinger Band — extended and may need to cool off
- Just broke above 20-day resistance — a level that was capping price, now cleared
- On a tear — up 54.5% over the last 5 days
- Beating the Small Ords index — relative strength of 1.43, so it's outpacing the pack
- Volatility is expanding fast — choppy price action, so buckle up
- Trading above the 200-day average — the long-term trend is on your side
- Low cash runway (3 quarters) - dilution risk
- Low P/S ratio (3.4x)
- Strong revenue growth (+181461%)
- Small-cap ($20-100M)
- Sentiment is mixed — no strong consensus either way
- Revenue growing at +181461% — the top line is moving in the right direction
- The bigger volume days are the up days — volume-weighted momentum is positive (2.45%/day)
- RBA hiking (-3pts)
Risk Signals
- RSI is running hot — overbought territory, so expect some pullback risk
- Stochastic is stretched into overbought — could need a breather
- Deeply negative margins (-61%)
- Not enough chatter to gauge sentiment — defaulting to neutral
- Long-term momentum is negative — down 42% over the past year
Expected next for NUZ
Window: 29 Oct to 12 Nov
The last 4 moved NUZ -2.7% on the day, on average — an observation, not a guide to what happens next.
Each date is labelled with how it is known. A date estimated from past filings is inferred from this company's own filing rhythm — it is not a confirmed date and not a statement about what the company intends to do. See the whole ASX calendar →
Recent Catalysts
NONE NIH funds Expanded Access Program for NUZ-001 in ALS
NONE Neurizon Appoints Chief Executive Officer
NONE Application for quotation of securities - NUZ
LOW Appendix 4E and 2026 Annual Report
Recent ASX Announcements
| 2026-09-08 | NIH funds Expanded Access Program for NUZ-001 in ALS PRICE SENSITIVE |
| 2026-09-06 | Neurizon Appoints Chief Executive Officer PRICE SENSITIVE |
| 2026-08-26 | Application for quotation of securities - NUZ |
| 2026-08-25 | Appendix 4G and Corporate Governance Statement |
| 2026-08-25 | Appendix 4E and 2026 Annual Report PRICE SENSITIVE |
Key Metrics
$59.6M
Market Cap
773K
Avg Volume
1.4x
Vol Ratio
$0.05 — $0.17
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-137.9%
ROE
-61.0%
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | fail | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | neutral | Float: 76% |
| L | Leader vs Laggard | pass | RS: 18 |
| I | Institutional Sponsorship | insufficient_data | Inst: 0% |
| M | Market Direction | neutral | Neutral |
Sector: Healthcare
110 tickers in this sector
View all Healthcare signals →Browse all ASX tickers A–Z →Track NUZ and 2,200+ ASX stocks
Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.
No credit card required